Endocrinology

Your Article Summary

See Latest Articles

Relationship between 3-month changes in biochemical markers of bone remodelling and changes in bone mineral density and fracture incidence in patients treated with strontium ranelate for 3 years
Osteoporosis International, 10/13/09

Bruyère O et al. – Short-term changes in biochemical markers of bone formation are associated with future BMD changes in patients treated with strontium ranelate, suggesting a bone-forming activity of this treatment, but are not appropriate to monitor the efficacy of strontium ranelate at the individual level.

• From the SOTI and TROPOS trials, bone-specific alkaline phosphatase (BALP), C-terminal propeptide of type I procollagen (PICP), serum C-terminal telopeptides (S-CTX) and urine N-terminal telopeptides of type I collagen (U-NTX) assessed at baseline and after 3 months
• 2373 women included

• Multiple regression analysis showed 3-month changes in PICP and BALP but not s-CTX I nor s-NTX I significantly associated with 3-year BMD changes at lumbar spine and femoral neck
• Changes in s-CTX I, PICP and BALP significantly associated with change in total proximal femur BMD
• Changes in biochemical markers explain < 8% of BMD changes
• 3-month changes in BALP, PICP s-CTX I and s-NTX I not significantly associated with fracture incidence

Today in Bone Metabolism...keeping you current

Receive free subspecialty "5-minute updates" via email

Osteonecrosis of the jaw correlated to bisphosphonate therapy in non-oncologic patients: Clinicopathological features of 24 patients
Journal of Rheumatology, 11/09/09

Bisphosphonate therapy: When not to monitor BMD
The Journal of Family Practice, 11/02/09

Effect of Rosiglitazone, Metformin, and Glyburide on Bone Biomarkers in Patients with Type 2 Diabetes
Journal of Clinical Endocrinology and Metabolism, 11/10/09

See All of Bone Metabolism